Company Name : Sharon Bio-Medicine Ltd
Address : C-312, BSEL Tech Park, Sector 30(A), Vashi, Navi Mumbai- 400703
Tel No: 91 22 67944000
Email : info@sharonbio.com, domestic@sharonbio.com
Website : http://www.sharonbio.com/
Company Profile
Sharon Bio-Medicine Limited is a Indian Pharmaceutical, Company listed at Bombay Stock Exchange. Over the years it has evoked from being a manufacturer of Intermediates & Active to now providing a range of Pharmaceutical products & services including Animal Toxicology and Manufacturing of Finished Dosages
Sharon was predominantly been known for its strengths in development & manufacturing of Pharmaceutical Intermediates & Actives. In 2007 with a focus on high quality standards Sharon ventured into the Finished product segment set up a Oral Solid dosage manufacturing facility at Dehradoon, India and later complimented its strategy by setting up an GMP compliant API Facility near Mumbai. With European regulatory approvals for two of its manufacturing facilities the longterm benefits of an integrated business model (API+Finished Products) are now being realized
Sharon’s longterm focus is to be an integrated service provider for its customers & adding competitive advantage to its customer’s products throughout its life cycle.
Services offered are:
• Preclinical Toxicology on small animals
• Chemical Process Development & Scale up
• Formulation Development
• Analytical Method Development
• DMF & Dossier preparation. (Sharon also undertakes joint development projects for ANDA & CD Dossiers.)
• Commercial Manufacturing of Intermediates, Actives, Finished Dosages.
• Stability monitoring for the entire shelf life of the product.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…